{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/107520"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/107520","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"A framework to evaluate interoperable data exchange models for Drug Supply Chain Security Act compliance","abstract":"The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry.","abstract_html":"The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry.","abstract_has_math":false,"creators":["Chung, Peter Wontae","Zhang, Tao"],"institution":"Massachusetts Institute of Technology","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Massachusetts Institute of Technology. Supply Chain Management Program.","school":null,"contributors":[],"advisors":["André Carrel."],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016","date_published":"2016","updated_at":"2026-07-22T22:22:20Z","subjects":["Supply Chain Management Program.","Engineering Systems Division."],"languages":["eng"],"rights":["MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission."],"rights_urls":["http://dspace.mit.edu/handle/1721.1/7582"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/1721.1/107520","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["André Carrel."]},{"key":"dc:contributor.department","label":"Department","values":["Massachusetts Institute of Technology. Supply Chain Management Program.","Massachusetts Institute of Technology. Engineering Systems Division."]},{"key":"dc:contributor.other","label":"Dc Contributor Other","values":["Massachusetts Institute of Technology. Engineering Systems Division."]},{"key":"dc:creator","label":"Author","values":["Chung, Peter Wontae","Zhang, Tao"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-03-20T19:38:09Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2017-03-20T19:38:09Z"]},{"key":"dc:date.issued","label":"Date","values":["2016"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Supply Chain Management Program.","Engineering Systems Division."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://dspace.mit.edu/handle/1721.1/7582"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/1721.1/107520"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis: M. Eng. in Logistics, Massachusetts Institute of Technology, Supply Chain Management Program, 2016.","Cataloged from PDF version of thesis.","Includes bibliographical references (page 50)."]},{"key":"dc:description.abstract","label":"Abstract","values":["The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["M. Eng. in Logistics"]},{"key":"dc:title","label":"Title","values":["A framework to evaluate interoperable data exchange models for Drug Supply Chain Security Act compliance"]}]}],"canonical_facts":{"dc:contributor.advisor":["André Carrel."],"dc:contributor.department":["Massachusetts Institute of Technology. Supply Chain Management Program.","Massachusetts Institute of Technology. Engineering Systems Division."],"dc:contributor.other":["Massachusetts Institute of Technology. Engineering Systems Division."],"dc:creator":["Chung, Peter Wontae","Zhang, Tao"],"dc:date.accessioned":["2017-03-20T19:38:09Z"],"dc:date.available":["2017-03-20T19:38:09Z"],"dc:date.issued":["2016"],"dc:description":["Thesis: M. Eng. in Logistics, Massachusetts Institute of Technology, Supply Chain Management Program, 2016.","Cataloged from PDF version of thesis.","Includes bibliographical references (page 50)."],"dc:description.abstract":["The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry."],"dc:description.degree":["M. Eng. in Logistics"],"dc:identifier.uri":["http://hdl.handle.net/1721.1/107520"],"dc:language.iso":["eng"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission."],"dc:rights.uri":["http://dspace.mit.edu/handle/1721.1/7582"],"dc:subject":["Supply Chain Management Program.","Engineering Systems Division."],"dc:title":["A framework to evaluate interoperable data exchange models for Drug Supply Chain Security Act compliance"],"dc:type":["Thesis"]},"updated_at":"2026-07-22T22:22:20Z"}